The clinical importance of Gal3 in AD is underscored by genetic and pathological evidence: LGALS3 variants are linked to increased AD risk, Gal3 is elevated in patient brains, including genetic and early onset AD (Rotshenker, 2022), and enriched in plaque-associated microglia, and functionally, it promotes amyloid aggregation and potentiates TREM2-DAP12 signaling (Boza-Serrano et al., 2019). Here, LGALS3 is linked to Alzheimer disease.